<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651791</url>
  </required_header>
  <id_info>
    <org_study_id>USPIO-MSC1</org_study_id>
    <nct_id>NCT03651791</nct_id>
  </id_info>
  <brief_title>In Vivo Tracking of USPIO Labeled MSC in the Heart</brief_title>
  <acronym>USPIO-MSC</acronym>
  <official_title>In Vivo MRI Tracking of Mesenchymal Stromal Cells Labeled With Ultra-Small Paramagnetic Iron Oxide Particles After Intramyocardial Transplantation in Patients With Chronic Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the ability to trace iron oxide-labeled mesenchymal stromal cells with magnetic
      resonance imaging (MRI) after NOGA-guided injection therapy into the myocardium in patients
      with ischemic heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims:

      To evaluate the ability to trace iron oxide-labeled mesenchymal stromal cells with magnetic
      resonance imaging (MRI) after NOGA-guided injection therapy into the myocardium.

      To evaluate the safety and efficacy of treatment with iron oxide-labeled mesenchymal stromal
      cells to form new heart muscle cells and blood vessels in the myocardium submitted by
      NOGA-guided injection therapy in the myocardium in order to improve myocardial blood flow and
      reduce patients' symptoms.

      Patient Population:

      Patients with coronary artery disease not treatable with additional bypass surgery or
      percutaneous coronary intervention who have angina pectoris (Canadian Cardiovascular Society
      (CCS) class II-III) or angina equivalent shortness of breath (New York Heart Association
      (NYHA) class II -III).

      Study Design A prospective, non-randomized, pilot study including 5-10 patients. Patients
      will by means of the percutaneous NOGA injection catheter system receive 12-15
      intramyocardial injections. The number depending on the amount of cultured cells and
      distributed uniformly in the peripheral zone of a presumed ischemic area in the left
      ventricle demonstrated by angiography, magnetic resonance imaging and NOGA mapping.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MSC identification using MRI in-vivo on day 0</measure>
    <time_frame>24 hours</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 0 after injection into the myocardium by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo on day 1</measure>
    <time_frame>1 day</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo on day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells on day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo after 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells after 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo after 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells after 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo after 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSC identification using MRI in-vivo after 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Being able to identify the iron-oxide labeled mesenchymal stromal cells after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac pump function changes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Left ventricular ejection fraction, systolic and diastolic volumes after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac pump function changes</measure>
    <time_frame>26 weeks</time_frame>
    <description>Left ventricular ejection fraction, systolic and diastolic volumes after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS class</measure>
    <time_frame>12 weeks</time_frame>
    <description>Canadian Cardiovascular Society (CCS) class after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS class</measure>
    <time_frame>26 weeks</time_frame>
    <description>Canadian Cardiovascular Society (CCS) class after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Seattle Angina Questionnaire after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire</measure>
    <time_frame>26 weeks</time_frame>
    <description>Seattle Angina Questionnaire after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly number of angina attacks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly number of angina attacks after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly number of angina attacks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Weekly number of angina attacks after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly nitroglycerin consumption</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly nitroglycerin consumption after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly nitroglycerin consumption</measure>
    <time_frame>26 weeks</time_frame>
    <description>Weekly nitroglycerin consumption after 26 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events registration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>USPIO labeled MSC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>USPIO labeled MSC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>USPIO labeled MSC injection</intervention_name>
    <description>USPIO labeled MSC injection</description>
    <arm_group_label>USPIO labeled MSC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 30 and 80 years.

          -  Signed informed consent.

          -  Chronic stable ischemic heart disease

          -  New York Heart Association (NYHA) class II-IV or Canadian Cardiovascular Society (CCS)
             class II-IV

          -  Maximal tolerable angina and/or heart failure medication.

          -  Angiography within 12 months of inclusion. Angiography must have at least one larger
             coronary vessel with a significant stenosis with no option for revascularization
             (Angiographies evaluated by an independent thoracic surgeon and an interventional
             cardiologist).

          -  Patients who have had revascularization done within 6 months of inclusion must have a
             new angiography at least 4 months after the intervention to rule out early restenosis.

        Exclusion Criteria:

          -  Pregnant or fertile women.

          -  Clinical significant anemia, leukopenia, leukocytosis or thrombocythemia.

          -  Diminished functional capacity for other reasons such as: chronic obstructive
             pulmonary disease (COLD) with Forced Expiratory Volume in 1 second (FEV1)&lt;1 L/min,
             moderate to severe claudication or morbid obesity.

          -  Patients with reduced immune response or treated with immunosuppressive medication.

          -  Moderate to severe valvular disease or valvular disease with option for valvular
             surgery.

          -  Acute coronary syndrome with elevation of coronary markers, stroke or Transitory
             Cerebral Ischemia (TCI) within 6 weeks of inclusion.

          -  History with malignant disease within 5 years of inclusion or suspected malignity.

          -  Other experimental treatment within 4 weeks of baseline evaluation.

          -  Other revascularization treatment within 4 months of treatment.

          -  Contraindications for Magnetic Resonance Imaging (MRI) such as: Claustrophobia,
             pacemaker, Implantable Cardioverter Defibrillator (ICD) unit, metal fragments or metal
             implants in the cranium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, MD DMSc</last_name>
    <role>Study Director</role>
    <affiliation>The Heart Centre, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <reference>
    <citation>Mathiasen AB, Hansen L, Friis T, Thomsen C, Bhakoo K, Kastrup J. Optimal labeling dose, labeling time, and magnetic resonance imaging detection limits of ultrasmall superparamagnetic iron-oxide nanoparticle labeled mesenchymal stromal cells. Stem Cells Int. 2013;2013:353105. doi: 10.1155/2013/353105. Epub 2013 Mar 19.</citation>
    <PMID>23577035</PMID>
  </reference>
  <reference>
    <citation>Hansen L, Hansen AB, Mathiasen AB, Ng M, Bhakoo K, Ekblond A, Kastrup J, Friis T. Ultrastructural characterization of mesenchymal stromal cells labeled with ultrasmall superparamagnetic iron-oxide nanoparticles for clinical tracking studies. Scand J Clin Lab Invest. 2014 Aug;74(5):437-46. doi: 10.3109/00365513.2014.900698. Epub 2014 Apr 15.</citation>
    <PMID>24734781</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anders Bruun Mathiasen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

